1. EGYPT PHARMA market
performance
Prepared by: Walid Saafan
April 2010

2. Leading corporate performance
03/10 YTD-03/10 MAT-03/10
Value. Inc.Sales GR% MS%. MS G/L Ev.Index Value. Inc.sales GR%. MS%. MS G/L Ev.Index Value. Inc.Sales GR%. MS%. MS G/L Ev.Index
Total Market 1,333.4 15.0% 3,904.8 15.9% 15,459.1 18.9%
GLAXOSMITHKLINE* 127.2 28.3 1 28.6% 6 9.54% 1.01% 111.8% 316.9 40.9 1 14.8% 14 8.11% -0.07% 99.1% 1,396.7 470.3 1 50.8% 2 9.03% 1.91% 126.8%
PHARCO* 92.8 12.8 2 15.9% 10 6.96% 0.06% 100.8% 295.7 38.6 3 15.0% 13 7.57% -0.06% 99.2% 1,114.9 136.4 3 13.9% 18 7.21% -0.31% 95.8%
NOVARTIS 92.2 12.4 3 15.5% 11 6.91% 0.03% 100.4% 272.6 38.9 2 16.6% 10 6.98% 0.05% 100.7% 1,091.0 177.0 2 19.4% 11 7.06% 0.03% 100.4%
EIPICO* 70.1 2.8 12 4.2% 19 5.25% -0.55% 90.6% 223.0 28.7 5 14.7% 15 5.71% -0.06% 99.0% 857.4 124.4 6 17.0% 14 5.55% -0.09% 98.4%
SANOFI AVENTIS* 69.8 2.9 11 4.3% 18 5.24% -0.54% 90.7% 219.2 25.5 6 13.1% 16 5.61% -0.14% 97.6% 870.5 135.9 4 18.5% 12 5.63% -0.02% 99.7%
AMOUN PHARM.CO. 57.8 8.6 4 17.6% 8 4.33% 0.09% 102.2% 169.7 37.5 4 28.4% 6 4.35% 0.42% 110.8% 657.4 102.6 7 18.5% 13 4.25% -0.01% 99.7%
PFIZER* 50.3 1.8 17 3.7% 20 3.78% -0.41% 90.2% 150.5 5.8 17 4.0% 21 3.85% -0.44% 89.8% 624.8 22.0 21 3.6% 22 4.04% -0.59% 87.2%
EVA PHARMA 40.1 8.5 5 27.0% 7 3.01% 0.28% 110.4% 100.7 18.2 10 22.0% 9 2.58% 0.13% 105.3% 376.7 81.6 9 27.7% 7 2.44% 0.17% 107.4%
SIGMA* 34.1 2.4 13 7.5% 14 2.56% -0.18% 93.5% 99.3 18.3 9 22.5% 8 2.54% 0.14% 105.7% 382.9 90.4 8 30.9% 6 2.48% 0.23% 110.1%
SERVIER* 33.2 2.3 16 7.3% 15 2.49% -0.18% 93.3% 101.0 9.0 15 9.8% 18 2.59% -0.14% 94.8% 394.6 44.5 13 12.7% 19 2.55% -0.14% 94.8%
MEDICAL UNION PHA* 29.5 1.0 20 3.5% 21 2.21% -0.25% 90.0% 82.5 5.2 19 6.7% 20 2.11% -0.18% 92.1% 331.9 46.6 12 16.3% 15 2.15% -0.05% 97.9%
ADWIA* 21.9 7.5 7 51.9% 3 1.64% 0.40% 132.1% 61.9 19.8 7 47.1% 3 1.59% 0.34% 127.0% 230.1 125.6 5 120.1% 1 1.49% 0.68% 185.2%
MULTIAPEX PHARM. 21.4 5.8 9 37.6% 4 1.60% 0.26% 119.6% 60.4 15.8 12 35.5% 4 1.55% 0.22% 116.9% 224.9 56.1 11 33.3% 5 1.45% 0.16% 112.1%
MERCK SERONO 20.8 2.3 14 12.3% 12 1.56% -0.04% 97.6% 61.8 13.3 13 27.4% 7 1.58% 0.14% 110.0% 239.2 68.8 10 40.4% 3 1.55% 0.24% 118.1%
SEDICO 20.4 1.1 19 5.5% 16 1.53% -0.14% 91.7% 55.8 4.5 20 8.9% 19 1.43% -0.09% 93.9% 227.8 24.8 20 12.2% 20 1.47% -0.09% 94.4%
ASTRAZENECA* 18.9 1.7 18 9.6% 13 1.41% -0.07% 95.3% 56.3 7.8 16 16.2% 11 1.44% 0.00% 100.3% 220.9 43.6 14 24.6% 8 1.43% 0.07% 104.8%
DELTA* 18.8 8.0 6 73.7% 1 1.41% 0.48% 151.0% 46.8 15.9 11 51.6% 2 1.20% 0.28% 130.9% 150.6 28.3 17 23.2% 10 0.97% 0.03% 103.6%
GLOBAL NAPI 17.5 6.6 8 60.4% 2 1.31% 0.37% 139.4% 47.3 18.3 8 63.3% 1 1.21% 0.35% 140.9% 163.3 40.8 15 33.3% 4 1.06% 0.11% 112.2%
NESTLE* 15.6 2.3 15 17.1% 9 1.17% 0.02% 101.8% 48.6 11.7 14 31.6% 5 1.25% 0.15% 113.6% 187.2 25.5 19 15.7% 16 1.21% -0.03% 97.4%
SCHERING PLOUGH* 15.1 0.7 21 5.0% 17 1.13% -0.11% 91.3% 47.5 4.4 21 10.2% 17 1.22% -0.06% 95.1% 209.4 28.1 18 15.5% 17 1.35% -0.04% 97.2%
JOHNSON E JOHNSON* 14.8 -1.0 22 -6.6% 22 1.11% -0.26% 81.2% 42.7 -0.4 22 -0.9% 22 1.09% -0.19% 85.5% 185.1 20.0 22 12.1% 21 1.20% -0.07% 94.3%
HIKMA PLC* 14.7 3.5 10 31.3% 5 1.10% 0.14% 114.1% 42.9 5.6 18 15.1% 12 1.10% -0.01% 99.3% 174.7 33.8 16 24.0% 9 1.13% 0.05% 104.3%
Total 67.25% 66.67% 66.70%
Total pharma market grew by +15% MTD, +16% YTD & 19% MAT
Xx outperform the market in Mar with GR +xx%, +15% YTD & xx% MAT
Leading MNCs showed moderate performance with slight decline in MS% (Q1)
EGYPT PHARMA Market performance -
Walid Saafan 04.10

3. Top 10 classes
Xx presented in xx
out of the leading 10
classes, leading
position in xx classes.
EGYPT PHARMA Market performance -
Walid Saafan 04.10

4. Top 30 products in the market
(17% of the total market)
Xx has xx products
presented in the top
30 products in the
market
EGYPT PHARMA Market performance -
Walid Saafan 04.10

5. XX market performance
High sales momentum
in Q1 reaching the xx
highest sales of xx Mio
EGP and MS% xx%
Leading corporate show
moderate performance
in Q1
EGYPT PHARMA Market performance -
Walid Saafan 04.10

6. Xx leading products performance within
relevant markets
Leadership position in xx (out of 10) leading brands
EGYPT PHARMA Market performance -
Walid Saafan 04.10

7. New introductions in the market (> 1 Mio EGP)
Xx led the market in terms of new introduction with xx new brands and xx new packs,
contributed with an additional sales of xx Mio EGP (xx% of the total introductions in the
market).
EGYPT PHARMA Market performance -
Walid Saafan 04.10

8. THANK YOU
EGYPT PHARMA Market performance -
Walid Saafan 04.10